(Legal Fee Tracker is a weekly feature focused on attorney compensation. Please send tips or suggestions to ...

Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.

We recently compiled a list of the Billionaire Prem Watsa’s Top 15 Long-Term Stock Picks. In this article, we are going to ...

Merck and Eisai said on Friday a combination of their cancer therapies failed to extend the lives of patients with a type of ...

Department of Health and Human Services (HHS) secretary nominee Robert F. Kennedy Jr. plans to continue to receive referral fees from a law firm that is suing pharma powerhouse Merck & Co. | ...

Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...

Merck KGaA (Merck) and Opentrons Labworks have announced a partnership to automate assay kits on a ‘custom’ Opentrons Flex ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The secretary of Health and Human Services nominee wrote in an ethics agreement that he would keep receiving contingency fees.

A recent health news roundup explores legal, financial, and strategic developments. Highlights include Robert F. Kennedy ...

Herrmann will continue in her role as chief of staff to EVP and chief communications and public affairs officer Cristal Downing.